Panacea Biotec Peer Comparison

NSE: PANACEABIO | BSE: 531349

₹395.50

₹2.25 (0.57%)

As on 28-Aug-2026IST

Market cap

₹2,418 Cr

Revenue (TTM)

₹673 Cr

P/E Ratio

P/B Ratio

2.9

Div. Yield

0 %

Edit

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	2,418	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	673	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	-8.92	735.15	678.07	666.92	169.62
Net Margin (%)	-1.30	26.88	28.10	20.60	6.90
RoE (%)	-1.37	19.16	19.73	18.75	20.76
Price to Earnings	--	29.25	28.74	28.35	104.74
Price-To-Book	2.89	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	672.64	2,569.77	2,287.33	3,229.67	2,432.06
Total Income	688.11	2,735.39	2,413.29	3,237.12	2,458.54
Total Expenditure	670.45	1,628.14	1,490.75	2,090.06	2,202.20
EBITDA	2.19	941.63	796.58	1,139.61	229.86
Depreciation	32.57	57.58	78.10	281.06	17.24
EBIT	-30.38	884.05	718.48	858.55	212.62
Interest	6.37	7.69	0.88	190.64	5.72
Other Income	15.47	165.62	125.96	7.45	26.48
Exceptional Items	10.92	-49.16	0.00	-17.24	-5.13
Profit before Tax	-10.36	992.82	843.56	658.12	228.25
Provision for Tax	-1.44	257.67	165.49	-8.80	58.63
Profit after Tax	-8.92	735.15	678.07	666.92	169.62

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	834.84	4,202.90	3,586.42	3,902.67	872.79
Minority Interest	1.80	0.00	-12.71	-21.81	0.00
Non-Current Liabilities	84.61	91.50	28.74	1,392.75	134.50
Current Liabilities	348.68	627.48	385.94	2,077.10	981.81
Total Liabilities	1,301.23	4,911.11	3,207.85	6,862.28	1,879.19

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	719.70	770.28	1,291.22	5,617.77	42.47
Current Assets	513.04	3,803.22	2,585.66	1,539.85	1,739.93
Total Assets	1,301.23	4,911.11	3,207.85	6,862.28	1,879.19
Total Debt*	22.21	2.50	0.55	2,421.66	0.00
Net Current Assets	164.36	3,175.74	2,199.72	-537.25	758.12
Contingent Liabilities	367.09	363.79	0.64	64.29	98.41

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	-27.37	659.75	432.37	1,065.01	65.36
Cash Flow from Investing Activities	64.98	-71.34	-334.73	-79.97	30.80
Cash from Financing Activities	-2.66	-205.34	-38.32	-881.32	-65.59
Net Cash Inflow / Outflow	34.95	383.07	59.32	103.72	30.57

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	-0.47	26.21	26.22	13.59	21.29
ROE (%)	-1.37	19.16	19.73	18.75	20.76
ROA (%)	-0.70	14.95	18.69	9.26	9.67
EBIT Margin (%)	-4.52	34.40	31.41	26.58	8.74
Net Margin (%)	-1.30	26.88	28.10	20.60	6.90
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	10.26	10.69	15.01	9.59	31.10
EBIT Growth (%)	36.14	24.14	18.45	16.84	-12.99
Net Profit Growth (%)	-180.22	-9.09	19.61	62.68	-7.49
EPS Growth (%)	99.13	14.40	17.73	67.41	-18.33
Book Value Growth (%)	-0.86	17.30	23.77	10.19	7.70

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	-211.83	27.87	28.74	27.66	102.37
Price / Book Value	2.89	4.88	5.08	4.51	19.65
Dividend Yield (%)	0.00	1.60	0.16	0.55	0.51
EV/EBITDA	1,064.19	19.53	22.88	17.94	75.34
Market Cap (₹ Cr)	2,698.97	18,318.10	15,219.80	19,292.77	21,515.93

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.03	0.00	0.00	0.24	0.00
Short term debt to equity ratio	--	0.00	0.00	0.14	--
Current Ratio	1.47	6.06	6.70	0.74	1.77
Quick Ratio	0.92	5.31	5.59	0.53	0.73
Interest Coverage	-0.63	130.11	959.59	4.45	40.90

	Panacea Biotec	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	10.93	7.07	36.10	21.07	8.79
Asset Turnover	0.53	0.52	0.63	0.45	1.39
Receivable days	42.20	29.10	110.70	54.07	35.81
Inventory Days	127.15	69.53	65.86	32.16	82.25
Payable days	339.61	76.77	105.88	140.91	124.39
Cash Conversion Cycle	-170.26	21.86	70.68	-54.68	-6.33

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.